Seres Therapeutics Inc (MCRB) Stock Price, Quote & News

Company Profile

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize gastrointestinal pathogens, enhance epithelial barrier integrity, and regulate immune response to prevent bacterial bloodstream infections, as well as other pathogen-associated negative clinical outcomes in patients undergoing allogeneic hematopoietic stem cell transplantation. Its other pipeline pr...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 945 9626

Website: www.serestherapeutics.com

Address:

101 Cambridgepark Drive, Cambridge, United States

jamstah Sep. 3 at 5:12 PM

$MCRB 10,000+ calls and growing and high borrow rate... Looks quite positive to me

1 · Reply

TotalChamp Sep. 3 at 4:28 PM

$MCRB nothing stopping this from going past $20

0 · Reply

mktfixer Sep. 3 at 4:26 PM

$MCRB $25 calls for oct being bought today Mkt is overall bullish yet we are stuck under a buck I'm thinking news early oct and not this month Everything is riding in october

0 · Reply

mktfixer Sep. 3 at 3:54 PM

$MCRB looks like the plan is to keep us under $20 until news

0 · Reply

Tritsortreat2020 Sep. 3 at 2:31 PM

$MCRB low volume covering. this stock is sold. well wake up soon with a 70%+ morning sooner than later

0 · Reply

BioCrazy1 Sep. 3 at 2:24 PM

$MCRB Seres attended H.C. Wainwright conferences in 2020 and 2021. Took the last 3 years off, I guess.

0 · Reply

mktfixer Sep. 3 at 2:15 PM

$MCRB lack of bidders and only large sellers makes this stock look pathetic...maybe that's their plan..It signals lack of confidence in moving forward...

0 · Reply

BioCrazy1 Sep. 3 at 2:13 PM

$MCRB It's been a month, but this butt plug can't update his LinkedIn. It explains his lackadaisical manner as CEO.

0 · Reply

Whiskeyunderthebed Sep. 3 at 2:08 PM

$MCRB We need some buyers to make this move.

0 · Reply

Thepark88 Sep. 3 at 1:58 PM

$MCRB there’s going to be a point shortly where we pa$$ $20 and never dip back below - it’s close

1 · Reply

Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference

Aug 6, 2025, 9:47 PM EDT - 27 days ago

Seres Therapeutics, Inc. (MCRB) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 7:00 AM EDT - 4 weeks ago

Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

SANA

Jul 29, 2025, 2:09 PM EDT - 5 weeks ago

Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthrough

Jul 22, 2025, 7:01 AM EDT - 6 weeks ago

Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025

Jul 22, 2025, 7:00 AM EDT - 6 weeks ago

Seres Therapeutics Announces Leadership Transition

May 27, 2025, 7:00 AM EDT - 3 months ago

Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting

May 7, 2025, 2:18 PM EDT - 4 months ago

Seres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call Transcript

May 7, 2025, 7:00 AM EDT - 4 months ago

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

Apr 29, 2025, 7:00 AM EDT - 4 months ago

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases

Apr 23, 2025, 7:00 AM EDT - 4 months ago

Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025

Mar 13, 2025, 11:04 AM EDT - 6 months ago

Seres Therapeutics, Inc. (MCRB) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 7:00 AM EDT - 6 months ago

Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 4, 2025, 7:00 AM EST - 6 months ago

Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025

Mar 3, 2025, 7:00 AM EST - 6 months ago

Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach

Jan 16, 2025, 7:00 AM EST - 8 months ago

Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale

Jan 9, 2025, 7:00 AM EST - 8 months ago

Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

Dec 16, 2024, 7:00 AM EST - 9 months ago

Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference

Nov 22, 2024, 7:00 AM EST - 10 months ago

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

Nov 13, 2024, 10:28 AM EST - 10 months ago

Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 7:00 AM EST - 10 months ago

Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024

Sep 30, 2024, 5:15 PM EDT - 1 year ago

Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A

Sep 27, 2024, 3:26 PM EDT - 1 year ago

Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestlé

Sep 26, 2024, 4:01 PM EDT - 1 year ago

Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30

Sep 23, 2024, 12:14 AM EDT - 1 year ago

Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade

Sep 13, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference

Sep 12, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

Aug 13, 2024, 3:35 PM EDT - 1 year ago

Seres Therapeutics, Inc. (MCRB) Q2 2024 Earnings Call Transcript

Aug 6, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024

Aug 6, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics Announces Signing of VOWST™ Asset Purchase Agreement with Nestlé Health Science

Jun 7, 2024, 4:00 PM EDT - 1 year ago

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 6, 2024, 7:00 AM EDT - 1 year ago

Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023

Jun 6, 2024, 6:30 AM EDT - 1 year ago

Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science

May 11, 2024, 5:34 PM EDT - 1 year ago

Seres Therapeutics, Inc. (MCRB) Q1 2024 Earnings Call Transcript

May 8, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 6, 2024, 9:30 AM EDT - 1 year ago

Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024

Apr 9, 2024, 7:00 AM EDT - 1 year ago

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

Apr 2, 2024, 2:10 AM EDT - 1 year ago

VKTX, JANX and these biotech stocks are surging in 2024

ARQT JANX VKTX AMLX RAPT RVNC

Mar 5, 2024, 3:33 PM EST - 1 year ago

Seres Therapeutics, Inc. (MCRB) Q4 2023 Earnings Call Transcript

Mar 5, 2024, 7:00 AM EST - 1 year ago

Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Feb 28, 2024, 7:00 AM EST - 1 year ago

Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024

Feb 27, 2024, 7:00 AM EST - 1 year ago

Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference

Feb 26, 2024, 7:00 AM EST - 1 year ago

Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz

Jan 9, 2024, 7:00 AM EST - 1 year ago

Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155

Jan 4, 2024, 4:00 PM EST - 1 year ago

Seres Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Dec 7, 2023, 7:46 PM EST - 1 year ago

Seres Therapeutics Announces Presentation of Preliminary PK/PD and Safety Data for Investigational Microbiome Therapeutic SER-155 at ASH 2023

Nov 28, 2023, 9:18 AM EST - 1 year ago

Seres Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023; Webcast at 3:30 p.m. ET

Nov 4, 2023, 11:52 AM EDT - 1 year ago

Seres Therapeutics, Inc. (MCRB) Q3 2023 Earnings Call Transcript

Nov 2, 2023, 7:00 AM EDT - 1 year ago

Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST™ Net Sales of $7.6 Million

jamstah Sep. 3 at 5:12 PM

$MCRB 10,000+ calls and growing and high borrow rate... Looks quite positive to me

1 · Reply

TotalChamp Sep. 3 at 4:28 PM

$MCRB nothing stopping this from going past $20

0 · Reply

mktfixer Sep. 3 at 4:26 PM

$MCRB $25 calls for oct being bought today Mkt is overall bullish yet we are stuck under a buck I'm thinking news early oct and not this month Everything is riding in october

0 · Reply

mktfixer Sep. 3 at 3:54 PM

$MCRB looks like the plan is to keep us under $20 until news

0 · Reply

Tritsortreat2020 Sep. 3 at 2:31 PM

$MCRB low volume covering. this stock is sold. well wake up soon with a 70%+ morning sooner than later

0 · Reply

BioCrazy1 Sep. 3 at 2:24 PM

$MCRB Seres attended H.C. Wainwright conferences in 2020 and 2021. Took the last 3 years off, I guess.

0 · Reply

mktfixer Sep. 3 at 2:15 PM

$MCRB lack of bidders and only large sellers makes this stock look pathetic...maybe that's their plan..It signals lack of confidence in moving forward...

0 · Reply

BioCrazy1 Sep. 3 at 2:13 PM

$MCRB It's been a month, but this butt plug can't update his LinkedIn. It explains his lackadaisical manner as CEO.

0 · Reply

Whiskeyunderthebed Sep. 3 at 2:08 PM

$MCRB We need some buyers to make this move.

0 · Reply

Thepark88 Sep. 3 at 1:58 PM

$MCRB there’s going to be a point shortly where we pa$$ $20 and never dip back below - it’s close

1 · Reply

Electhim Sep. 3 at 1:56 PM

$MCRB let’s hope this conference is different than the ones that we’ve been used to for the last 2 1/2 years

0 · Reply

BIOhmygod Sep. 3 at 7:32 AM

$MCRB Why is it struggling to break the $20 resistance level?

1 · Reply

MikeyDread Sep. 3 at 5:01 AM

$MCRB play along wall st games…get paid…the fun has just begun

0 · Reply

BioCrazy1 Sep. 3 at 1:55 AM

$MCRB Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will attend the upcoming H.C. Wainwright Global Investment Conference in New York City and will present a company overview at 3:00 p.m. ET on September 8, 2025. I'm not sure how to read into them attending this conference. Are they going to beg for money. It's not like their story isn't known. Standing on the street corner begging for money is not a good look. Make Shaff4brains do it!

0 · Reply

Numbersandfacts Sep. 2 at 10:07 PM

$MCRB an oldie but a goodie " Nestlé chief executive Laurent Freixe said his predecessor’s forays into new product categories that included health supplements “weakened the fabric of the organisation”, as he ruled out turning to major acquisitions or asset sales to boost growth" This is from The financial Times May 2025 https://www.ft.com/content/0877eae6-98b2-4c13-b98c-065bcdae2c8d It would be interested to hear what the philosophy of the new CEO is and how open he would be to acquisitions etc.

0 · Reply